Overview of guidelines for proper use of the G-CSF (2013 edition)

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Guidelines for proper use of the G-CSF (2001 edition) by the Japan Society of Clinical Oncology have been revised the first time in 12 years. The differences between the first edition and the new one are as follows: The new guidelines (2013 edition) adopted the clinical question format, and used the level of evidence and recommendation grades, along with the Handbook of Clinical Guidelines of Minds (2007 edition). There are relatively few evidence-based randomized controlled trials (RCTs) that can inform G-CSF use in Japan at present. Thus, we had to select the evidence from RCTs conducted in Europe and the USA when setting the recommendation level. Guidelines from Europe and the USA were also referred to; however, because the incidence of febrile neutropenia (FN) is presumed to differ between Japan and the USA/Europe, the clinical trials conducted in Japan were investigated as much as possible. New chapters on topics such as biosimilars, pegfilgrastim (domestic non-release), and the dosage and method of G-CSF administration (medical insurance in Japan) were added. The chemotherapy regimen-specific incidence of FN in Japan for primary prophylactic G-CSF administration and G-CSF use in hematological malignancy were described in detail. Nurses, pharmacists, and medical doctors participated in guideline steering committee, because the new guidelines are directed at a wide range of health care workers.

Original languageEnglish
Pages (from-to)687-690
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume41
Issue number6
Publication statusPublished - 2014

Fingerprint

Granulocyte Colony-Stimulating Factor
Japan
Guidelines
Febrile Neutropenia
Biosimilar Pharmaceuticals
Randomized Controlled Trials
Medical Oncology
Incidence
Hematologic Neoplasms
Insurance
Pharmacists
Nurses
Clinical Trials
Delivery of Health Care
Drug Therapy

Keywords

  • Biosimilars
  • G-CSF
  • Pegfilgrastim
  • Regimen-specific risk factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Overview of guidelines for proper use of the G-CSF (2013 edition). / Kiura, Katsuyuki.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 41, No. 6, 2014, p. 687-690.

Research output: Contribution to journalArticle

@article{13ae73e0fdea4b91b2c4599b2e6b5e29,
title = "Overview of guidelines for proper use of the G-CSF (2013 edition)",
abstract = "Guidelines for proper use of the G-CSF (2001 edition) by the Japan Society of Clinical Oncology have been revised the first time in 12 years. The differences between the first edition and the new one are as follows: The new guidelines (2013 edition) adopted the clinical question format, and used the level of evidence and recommendation grades, along with the Handbook of Clinical Guidelines of Minds (2007 edition). There are relatively few evidence-based randomized controlled trials (RCTs) that can inform G-CSF use in Japan at present. Thus, we had to select the evidence from RCTs conducted in Europe and the USA when setting the recommendation level. Guidelines from Europe and the USA were also referred to; however, because the incidence of febrile neutropenia (FN) is presumed to differ between Japan and the USA/Europe, the clinical trials conducted in Japan were investigated as much as possible. New chapters on topics such as biosimilars, pegfilgrastim (domestic non-release), and the dosage and method of G-CSF administration (medical insurance in Japan) were added. The chemotherapy regimen-specific incidence of FN in Japan for primary prophylactic G-CSF administration and G-CSF use in hematological malignancy were described in detail. Nurses, pharmacists, and medical doctors participated in guideline steering committee, because the new guidelines are directed at a wide range of health care workers.",
keywords = "Biosimilars, G-CSF, Pegfilgrastim, Regimen-specific risk factor",
author = "Katsuyuki Kiura",
year = "2014",
language = "English",
volume = "41",
pages = "687--690",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - Overview of guidelines for proper use of the G-CSF (2013 edition)

AU - Kiura, Katsuyuki

PY - 2014

Y1 - 2014

N2 - Guidelines for proper use of the G-CSF (2001 edition) by the Japan Society of Clinical Oncology have been revised the first time in 12 years. The differences between the first edition and the new one are as follows: The new guidelines (2013 edition) adopted the clinical question format, and used the level of evidence and recommendation grades, along with the Handbook of Clinical Guidelines of Minds (2007 edition). There are relatively few evidence-based randomized controlled trials (RCTs) that can inform G-CSF use in Japan at present. Thus, we had to select the evidence from RCTs conducted in Europe and the USA when setting the recommendation level. Guidelines from Europe and the USA were also referred to; however, because the incidence of febrile neutropenia (FN) is presumed to differ between Japan and the USA/Europe, the clinical trials conducted in Japan were investigated as much as possible. New chapters on topics such as biosimilars, pegfilgrastim (domestic non-release), and the dosage and method of G-CSF administration (medical insurance in Japan) were added. The chemotherapy regimen-specific incidence of FN in Japan for primary prophylactic G-CSF administration and G-CSF use in hematological malignancy were described in detail. Nurses, pharmacists, and medical doctors participated in guideline steering committee, because the new guidelines are directed at a wide range of health care workers.

AB - Guidelines for proper use of the G-CSF (2001 edition) by the Japan Society of Clinical Oncology have been revised the first time in 12 years. The differences between the first edition and the new one are as follows: The new guidelines (2013 edition) adopted the clinical question format, and used the level of evidence and recommendation grades, along with the Handbook of Clinical Guidelines of Minds (2007 edition). There are relatively few evidence-based randomized controlled trials (RCTs) that can inform G-CSF use in Japan at present. Thus, we had to select the evidence from RCTs conducted in Europe and the USA when setting the recommendation level. Guidelines from Europe and the USA were also referred to; however, because the incidence of febrile neutropenia (FN) is presumed to differ between Japan and the USA/Europe, the clinical trials conducted in Japan were investigated as much as possible. New chapters on topics such as biosimilars, pegfilgrastim (domestic non-release), and the dosage and method of G-CSF administration (medical insurance in Japan) were added. The chemotherapy regimen-specific incidence of FN in Japan for primary prophylactic G-CSF administration and G-CSF use in hematological malignancy were described in detail. Nurses, pharmacists, and medical doctors participated in guideline steering committee, because the new guidelines are directed at a wide range of health care workers.

KW - Biosimilars

KW - G-CSF

KW - Pegfilgrastim

KW - Regimen-specific risk factor

UR - http://www.scopus.com/inward/record.url?scp=84906269663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906269663&partnerID=8YFLogxK

M3 - Article

C2 - 25129080

AN - SCOPUS:84906269663

VL - 41

SP - 687

EP - 690

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 6

ER -